Autophagy, or 'self-eating' , refers to mechanisms of lysosome-dependent degradation of intracellular components, which are recycled for energy supply or other purposes. In most contexts, the term 'autophagy' denotes macroautophagy, the process by which a double membrane phagosomal structure is formed and engulfs material that is then degraded through lysosome fusion. An understanding of the role of autophagy in the heart is emerging, and autophagy is known to be involved in several cardiac disease processes. The rate of cardiomyocyte proliferation in the adult heart is extremely low, resulting in a limited capacity for myocyte replacement 1 . Therefore, intracellular renewal (that is, recycling) has an important role in determining cardio myocyte functionality and longevity. The process of autophagy in the myocardium is essential to prevent the accumulation of macromolecular aggregates and dysfunctional organelles and preserve cellular homeostasis, under both basal conditions and times of stress 2 . Cardiomyocyte autophagy is required for the survival of these cells in the neonatal heart during the postnatal period of nutrient deprivation 3 and, in the adult heart, acute energy stress provides a potent stimulus for autophagy 4 . As considered in detail in this Review, disturbance of autophagy has been identified in many cardiac diseases, including hypertrophy, pressure-overload heart failure, ischaemic heart disease, as well as diabetic and age-related cardiomyopathies. However, the circumstances in which autophagy is a beneficial adaptive response to disease triggers, or a maladaptive response involving cell death, are not yet known. New tools for experimental manipu lation of autophagy in cardiac disease states are under development, and could lead to tissue-selective thera pies targeted specifically to the processes involved in macroautophagy. These tools will be of importance in distinguish ing macroautophagic processes and other related autophagic pathways also oper ational in most cell types, namely microautophagy (direct recruitment of cytosolic material to the lysosome 5 ), chaperonemediated autophagy or endosomal microautophagy (single protein-recruitment to endosomes or lysosomes 6,7 ), and mitochondria-derived vesicular autophagy (fusion of mitochondrial outer membranes with endosomes before lysosome degradation 8 ). The focus of this Review is on the pathways and processes of cardiac macroautophagy, and highlights advances in defining the role of macroautophagy subtypes selective for cellular cargo in the setting of myocardial stress. The 2016 Nobel Prize in Physiology or Medicine was awarded to Yoshinori Ohsumi for discoveries of mechanisms for Abstract | Autophagy is a ubiquitous cellular catabolic process responsive to energy stress. Research over the past decade has revealed that cardiomyocyte autophagy is a prominent homeostatic pathway, important in adaptation to altered myocardial metabolic demand. The cellular machinery of autophagy involves targeted direction of macromolecules and organelles for lysosomal degradation. Activation of autophagy has been identified as cardioprotective in some settings (that is, ischaemia and ischaemic preconditioning). In other situations, sustained autophagy has been linked with cardiopathology (for example, sustained pressure overload and heart failure). Perturbation of autophagy in diabetic cardiomyopathy has also been observed and is associated with both adaptive and maladaptive responses to stress. Emerging research findings indicate that various forms of selective autophagy operate in parallel to manage various types of catabolic cellular cargo including mitochondria, large proteins, glycogen, and stored lipids. In this Review, induction of autophagy associated with cardiac benefit or detriment is considered. The various static and dynamic approaches used to measure autophagy are critiqued, and current inconsistencies in the understanding of autophagy regulation in the heart are highlighted. The prospects for pharmacological intervention to achieve therapeutic manipulation of autophagic processes are also discussed.
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. Therefore, intracellular renewal (that is, recycling) has an important role in determining cardio myocyte functionality and longevity. The process of autophagy in the myocardium is essential to prevent the accumulation of macromolecular aggregates and dysfunctional organelles and preserve cellular homeostasis, under both basal conditions and times of stress 2 . Cardiomyocyte autophagy is required for the survival of these cells in the neonatal heart during the postnatal period of nutrient deprivation 3 and, in the adult heart, acute energy stress provides a potent stimulus for autophagy 4 . As considered in detail in this Review, disturbance of autophagy has been identified in many cardiac diseases, including hypertrophy, pressure-overload heart failure, ischaemic heart disease, as well as diabetic and age-related cardiomyopathies. However, the circumstances in which autophagy is a beneficial adaptive response to disease triggers, or a maladaptive response involving cell death, are not yet known. New tools for experimental manipu lation of autophagy in cardiac disease states are under development, and could lead to tissue-selective thera pies targeted specifically to the processes involved in macroautophagy. These tools will be of importance in distinguish ing macroautophagic processes and other related autophagic pathways also oper ational in most cell types, namely microautophagy (direct recruitment of cytosolic material to the lysosome 5 ), chaperonemediated autophagy or endosomal microautophagy (single protein-recruitment to endosomes or lysosomes 6, 7 ) , and mitochondria-derived vesicular autophagy (fusion of mitochondrial outer membranes with endosomes before lysosome degradation 8 ). The focus of this Review is on the pathways and processes of cardiac macroautophagy, and highlights advances in defining the role of macroautophagy subtypes selective for cellular cargo in the setting of myocardial stress. The 2016 Nobel Prize in Physiology or Medicine was awarded to Yoshinori Ohsumi for discoveries of mechanisms for 1 autophagy -pioneering work that began with investigations in nonmammalian cells in the 1990s. Given the recognition accorded to the fundamental investigative work of Ohsumi and colleagues, evaluation of current understanding in myocardial autophagy and the potential opportunities emerging for therapeutic intervention is timely.
The machinery of autophagy
In the heart, as in other tissues, the process of autophagy involves several protein complexes that select and degrade cellular components under the tight regulation of multiple signalling nodes. Two parallel processes are involved in the first stages of autophagy. A double-membrane preautophagosome structure is formed and elongated to enclose cellular cargo tagged for degradation (FIG. 1) . The autophagosome then fuses with a lysosome where acid-activated enzymes break down the contents to their constituent molecular building blocks 9 . Autophagosome membrane structures are thought to nucleate from endoplasmic reticulum, Golgi apparatus, or mitochondrial membranes, and require the collection and assembly of proteins at the preauto phagosome structure 10 . These proteins include the serine/ threonine-protein kinase ULK complex (ULK1 or 2, autophagy-related protein [Atg] 13, Atg101, FIP200) and the phosphatidylinositol 3-kinase (PI3K) complex (PI3K [class III], Beclin 1, Atg14) 9 . The dissociation of Beclin 1 from apoptosis regulator Bcl-2 is essential for Beclin 1 movement into the PI3K complex and is, therefore, an important regulator of autophagic activity 11 . The dual role of Bcl-2 in the suppression of apoptosis and initiation of autophagy can mediate reciprocal regulation of these two major processes that determine cell viability. Autophagy proceeds through the action of the PI3K complex, which produces the phospholipid PI3-phosphate thus attracting WIPI1, Atg9, and Atg2 to the preautophagosome to position these key proteins ready to expand the membrane into an autophagosome 9 . Next, the Atg16L1 complex (Atg16L1, Atg12, Atg5) is recruited to the forming autophagosome membrane by Ras-related protein (Rab) 33 (REF. 9 ). Incorporation and anchoring of Atg8 scaffold proteins into the autophagosome membrane requires lipidation mediated by Atg7 and Atg3 (REF. 9 ). Atg8 family proteins seem to have a dual role in the autophagosome; these proteins are essential for expanding the autophagosome membrane, and for recruiting cargo to be degraded 9 . The lipidation of Atg8 has been a useful tool for monitor ing autophagic activity. The lipid-attachment shifts the protein position by ~2 kDa (in sodium dodecyl sulfate polyacrylamide gel electrophoresis) and can, therefore, be detected by immunoblot to quantify the active ( lipidated) and inactive (non lipidated) forms 12 . Although the autophagosome construction process described above is generally accepted as conventional, other macroautophagy-like pathways can be operational. An alternative form of autophagy, which is independent of Atg5 and Atg7, has been described 12, 13 . This process might be a type of chaperone-mediated or endosomal-mediated autophagy, or could rely on molecular processes yet to be fully defined.
Cellular components destined for autophagic degradation can be recruited to the autophagosome in various ways. Ubiquitylation of protein aggregates can make them a target for specific adaptor molecules. The adaptor molecules position the ubiquitin-tagged proteins in the autophagosome via binding to lipidated Atg8 (REF. 9 ). Multiple mammalian Atg8 orthologues have been identi fied, along with a cohort of interacting (including adaptor) proteins 14 . Identification of cargo-specific Atg8 orthologues and adaptor proteins is an expanding area of research, and is considered in more detail below. The mechanism of autophagosome closure around the cargo is not well established, but could involve the SNARE (soluble NSF attachment protein receptors and homologues) complex, Atg2, Atg8, and Atg9. After closure, the autophagosome fuses with a lysosome. Autophagosomes can traffic along the cytoskeleton and various proteins from the Rab (Rab5 and Rab7), UVRAG (ultraviolet radiation resistance-associated gene protein), and SNARE (syntaxin [Stx] 7, Stx8, Stx17, VTI1b, and Vamp 7) families are thought to be involved in trafficking and lysosome fusion 15, 16 (FIG. 1) . The contents of the autophagolysosome are then degraded by lysosomal hydrolases (for example, esterases, proteases, glycosidases, nucleosidases, and lipases depending on cargo content). The breakdown products are exported from the autophagolysosome via routes that are not well characterized, but are likely to involve permease-mediated transport 17 . A change in autophagy can be evaluated in various ways. A 'snapshot' quantification (that is, a static measure) of autophagy-related proteins can provide information about comparative levels of participating proteins, which could help to determine whether autophagic drive is increased or decreased in the setting of chronic disease 12 . However, in some circumstances of acute and chronic autophagy induction, accumulation of autophagy-related proteins can be the result of impaired lysosome function rather than an increase in autophagic drive 18 . The operation of the autophagic machinery requires coordin ated regulation to avoid disturbance of cargo clearance, leading to an accumulation of auto phagosomes in the cytosol (indicative of impaired
Key points
• Autophagic breakdown of cellular components is regulated by multiple signalling networks, including insulin and 5ʹ-AMP-activated protein kinase pathways, and is essential for cardiomyocyte survival in response to stress • A new understanding of cargo-selective autophagy in the heart is emerging, relating to specific pathways for degradation of proteins (macrophagy), mitochondria (mitophagy), and glycogen (glycophagy) • Disturbances in cardiomyocyte autophagy are evident in numerous cardiac pathologies, including cardiac hypertrophy, pressure-overload heart failure, ischaemic heart disease, as well as diabetic and age-related cardiomyopathies • The cardioprotective effects of autophagy in acute energy stress are clear, but whether sustained elevation of autophagy in chronic disease states is beneficial or detrimental is not known • Autophagy is a potentially attractive therapeutic target in cardiopathology;
several new areas for investigation related to therapies for cardiomyocyte-specific and cargo-specific autophagy have been identified processing rather than elevated activity). To evaluate the extent of autophagy trafficking through the system (that is, a dynamic measure), pharmaco logical tools (such as chloroquine and bafilomycin) can be used to induce an acute block of autophagosome-lysosome fusion 18 . The subsequent accumulation of autophagy-related proteins provides a measure of underlying autophagosome throughput (that is, flux) 12, 19 . These approaches have provided important insights into the physiological and pathophysiological role of autophagy in the heart, which is discussed in more detail below.
Cargo-selective autophagy subtypes
As research into autophagy has evolved, the terminology 'macroautophagy' (versus microautophagy) has been primarily relevant to processes involving macroproteins, large protein aggregates, and organelles. With the advancing understanding of cargo-selective autophagy routes, the descriptor 'macroautophagy' can now be understood to represent a collection of degradation processes, each somewhat specialized in relation to the cargo processed. Given this broader understanding, adopting the term 'macrophagy' to apply specifically , and Atg101) and the movement of Beclin 1 away from apoptosis regulator Bcl-2 and into the phosphatidylinositol 3-kinase (PI3K) complex (comprising PI3K (class III), Beclin 1, and Atg14). The PI3K complex produces the phospholipid phosphatidylinositol 3-phosphate (PI(3)P), which attracts WD repeat domain phosphoinositide-interacting protein 1 (WIPI), Atg9, and Atg2 to the preautophagosome to position these key proteins ready to expand the membrane into an autophagosome. The Atg16L1 complex (comprising Atg16L1, Atg12, and Atg5) is recruited to the forming preautophagosome membrane by Ras-related protein (Rab) 33. Atg8 family proteins are incorporated into the membrane via Atg7-mediated and Atg3-mediated lipidation (PE), anchoring them into the double-membrane. Cellular cargo to be degraded is recruited into the autophagosome by adaptor proteins and bind to an Atg8 family member. The mechanism of autophagosome closure around the cargo is not well established, but might involve Atg2, Atg8, and Atg9. Autophagosomes can traffic along the cytoskeleton, and various proteins from the Rab (Rab5 and Rab7), UVRAG (ultraviolet radiation resistance-associated gene protein), and SNARE (soluble NSF attachment protein receptors and homologues; syntaxin [Stx] 7, Stx8, Stx17, vesicle transport through interaction with t-SNAREs homologue 1B [VTI1b], and vesicle-associated membrane protein [Vamp] 7) families are implicated in lysosome fusion. Lysosome-associated membrane glycoprotein (LAMP) 1 and LAMP2 have been implicated in various lysosomal functions, including maintaining lysosomal membrane integrity, autophagosome-lysosome fusion, and lysosome motility. The vacuolartype H + ATPase (V-ATPase) pumps protons across the lysosomal membrane to acidify the lumen. Hydrolases in the lysosome (blue circles) degrade the autophagosome contents. Chloroquine and bafilomycin are pharmacological agents used experimentally to block autophagosome-lysosome fusion (by neutralizing or preventing acidification) to assess autophagosome clearance. Nature Reviews | Cardiology to autophagic processing of protein macromolecules and aggregates seems appropriate, and will be used in this Review. Autophagic degradation processes have been described in various tissues for a range of cellular components including macroproteins or protein aggregates, endoplasmic reticulum, ribosomes, lipid droplets, peroxisomes, glycogen, and mitochondria. Cargo-selective machinery (specific adaptors and Atg8 partners) have been identified for some of these processes. In the myocardium, macrophagy processing has been investigated extensively. Understanding of the selective mechanisms involving mitochondrial and glycogen autophagy in the heart has advanced substantially in the past decade and, together with macrophagy, these processes are discussed in more detail below (FIG. 2) .
Macrophagy. Recruitment of cardiac protein aggregates into autophagosomes utilizes ubiquitin-tagging of target proteins, recognized by adaptor molecules that have both ubiquitin-binding domains and an Atg8-interacting motif, to connect with the forming autophagosome 20 . The ubiquitin-binding protein p62 (also known as sequestosome 1) is the key macrophagy adaptor and complexes with the Atg8 homologue LC3, which is activated by lipidation and mediates protein cargo incorporation into the forming phagosome. Detection of both p62 and lipidated LC3 (that is, conversion of cytosolic LC3-I to LC3-II) are used experimentally for characterization and localization of macrophagy in cardiac cells and tissues.
In noncardiac cells, evidence is emerging that ubiquitin-independent pathways for cargo recruitment might be important in autophagic clearance of protein aggregates 21 , but whether a similar process has a role in the heart is yet to be established. In an elegant feedback mechanism, amino acid availability was shown to be a potent regulator of macrophagy, probably mediated via mechanistic target of rapamycin (mTOR) signalling 22 . Although yet to be demonstrated in cardiomyocytes, in noncardiac cell types, elevated cytosolic amino acid levels activate mTOR complex 1 (mTORC1) by recruitment to the lysosome via recombination-activating gene (Rag) family proteins 22 . Activated mTOR inhibits the early steps of autophagosome formation (via ULK1/2) 23 and lysosomal biogenesis (via transcription factor EB [TFEB]) 24 in the heart. In the setting of amino acid depletion, mTORC1 dissociates from the lysosome (a process regulated by the translocation of the tuberous sclerosis complex to the lysosome), thus removing mTORC1 inhibition of autophagy and promoting autophagy-mediated 'resupply' of amino acids 22 . Protein breakdown in the heart mediated by macrophagy could be important in the regression of cardiac hypertrophy. Mice with cardiomyocyte-specific autophagy deficiency (Atg5 deletion) show impaired regression of cardiac hypertrophy after withdrawal of pressure-overload induced by angiotensin II infusion (withdrawal via osmotic minipump removal) 25 . Conversely, augmented autophagy (assessed by measurement of LC3 level) is a necessary component of the cardiomyocyte hypertrophic response under stress conditions 26, 27 . Therefore, protein turnover and synthesis are closely regulated by macrophagy, which is important in myocardial tissue plasticity; however, macrophagy might be permissive of growth in some contexts and limiting of growth in others. A detailed understanding of how macrophagy is regulated in these contrasting conditions is required to consider nuanced therapies in the settings of growth perturbation or proteotoxicity. proteins, including BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (Bnip3), Bnip3-like protein (also known as Nix), and p62, which bind to LC3 in the autophagosome membrane. Mitophagy is stimulated by reactive oxygen species (ROS), collapse of the mitochondrial membrane potential (mito Ψ), and low ATP levels. c | Glycophagy involves the tagging of glycogen with the adaptor protein starch-binding domain-containing protein 1 (STBD1), which recruits glycogen into the autophagosome by binding to γ-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1). Glycophagy might be regulated by its breakdown product, glucose. Nature Reviews | Cardiology Mitophagy. Acute and chronic perturbations in mitochondrial function drive adverse remodelling in many cardiac pathologies. Selective degradation of damaged or senescent mitochondria by mitochondrial autophagy (termed 'mitophagy') has an important role in maintaining energy homeostasis and reducing reactive oxygen species (ROS) produced by removal of dysfunctional mitochondria. Mitophagy is also essential to the removal of mitochondrial DNA that, through its similarity to bacterial DNA, can trigger immune responses via activation of inflammation mediated by Toll-like receptor 9. This process is exemplified by the cardiomyocyte-specific deletion of lysosomal DNase, which results in severe myocarditis and dilated cardio myopathy in mice subjected to pressure overload 28 . Oxidized mitochondrial DNA can also activate the inflammasome when released into the cytosol, promoting further inflammation 29 .
For mitophagy to proceed, mitochondria must first be segregated from the network before degradation, with proteins involved in mitochondrial fission evidently having an essential role 30 . In mice lacking dynamin 1-like protein (DRP1), an accumu lation of elongated dysfunctional mitochondria occurs coincident with impaired mitophagy and left ventricular dysfunction 30 . The mitochondrial perme ability transition pore might also be important for mitochondrial quality control in addition to its established role in inducing cell death. Low conductance activity or 'flickering' gives rise to transient mitochondrial depolariza tion, which might be important in the selection of mitochondria for mitophagy. Indeed, when mitochondrial permeability transition is inhibited by Cypd (the gene encoding cyclophilin D, also known as peptidyl prolyl isomerase D [Ppid]) knockout or treatment with cyclosporine A, cardio myocyte mito chondria accumulation occurs coincident with a reduction in autophagosome number 31 . The best-characterized mitophagy signalling pathway involves the proteins serine/threonine-protein kinase PINK1 and E3 ubiquitin-protein ligase Parkin, which trigger the removal of mitochondria in response to a fall in mitochondrial membrane potential. Healthy mitochondria import and degrade PINK1. Collapse of the mitochondrial membrane potential precludes PINK1 from entering the mitochondria, leading to its localization on the outer mitochondrial membrane 32 . Subsequent recruitment of Parkin enables ubiquitylation of multiple outer mitochondrial membrane proteins and recruitment of cargo adaptors (for example, p62), which orchestrate organelle engulfment by the auto phagosome 33 . The proapoptotic BH3-only proteins Bnip3 (BCL2/adenovirus E1B 19 kDa proteininteracting protein 3) and Bnip3L (Bnip3-like protein; also known as Nix) have been demonstrated to function as adaptors for recruiting mitochondria to the auto phagosome, by interacting with LC3 (REF. 34 ).
In non cardiac cells, the adaptor proteins NDP52 (calcium-binding and coiled-coil domain-containing protein 2) and optineurin have been found to participate in mitophagy 35 , and are recruited to the mitochondria in a PINK1-dependent, but Parkin-independent, manner 36 . A role for these specific adaptors in cardio myocyte mitophagy has not yet been demonstrated. In parallel with mitophagy, mitochondrial integrity might also be preserved by packaging selected damaged components into small vesicles, which bud off the mitochondria for trafficking directly to the lysosome 37, 38 . The activation of mitophagy is likely to make a substantial contribution to the protection mediated by ischaemic preconditioning 39 ; however, few thera peutic agents specifically activate mitophagy. The chemical uncouplers FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone) and 2,4-dinitrophenol have been used experimentally to demonstrate the dependence of activation of mitophagy on membrane potential. Both agents are cardioprotective at mild uncoupling concentrations 40, 41 . Activation of mitophagy is also necessary for the cardioprotection mediated by simvastatin 42 . New molecular tools have enabled mitochondrial turnover and mitophagy to be visualized in vivo with the generation of the transgenic MitoTimer, Mito-QC, and Mt-Keima transgenic mice [43] [44] [45] . These tools have facilitated important advances in the understanding of mitochondrial turnover and of the role of mitophagy in cardiac pathology, particularly in the context of ischaemia-reperfusion injury, which is discussed in more detail below.
Glycophagy.
Observations of glycogen localized to vacuoles and lysosomal structures have been reported sporadically. However, characterization of a glycogen-specific autophagy pathway and an understanding of the role of myocardial glycogen autophagy have emerged only in the past few years. In 1932, Joannes Pompe provided the first report of cardiac pathology and premature death linked with apparent glycogen 'storage' overload in the heart, a condition now known as Pompe disease 46 . In the early 1960s, Henri Hers discovered that cardiac accumulation of glycogen in these patients was caused by a deficiency in the lysosomal enzyme for glycogen breakdown -lysosomal α-glucosidase (also known as acid α-glucosidase) 47 . This finding highlighted the importance of autophagic-lysosomal processing of glycogen in the heart. Five decades later, specific autophagy adaptor-Atg8 homologue proteins involved in recruiting glycogen to the autophagosome have now been identi fied. Starch-binding domain-containing protein 1 (STBD1) contains a carbohydrate-binding domain for glycogen, and an Atg8-interacting-motif for binding to the 'autophagosome-forming' Atg8 family proteins 48 . Proteomic analysis of the human Atg8 subnetwork has identified that STBD1 interacts with Atg8 proteins from the γ-aminobutyric acid receptor-associated protein (GABARAP) subfamily, but not the LC3 subfamily 14 . In vitro colocalization studies in noncardiac cells have confirmed the interaction between STBD1 and γ-aminobutyric acid receptor-associated proteinlike 1 (GABARAPL1), and identified STBD1 to be a novel cargo-binding protein for glycogen recruitment into autophagosomes 49 .
Collectively, these findings demonstrate that glycogen autophagy utilizes specific adaptor-Atg8 scaffold protein partners, indicative of a selective ' glycophagy' process. In 2013, the glycophagy adaptor-Atg8 partner proteins STBD1 and GABARAPL1 were reported for the first time to be present in the mammalian myocardium, and that glycophagy is operational and is responsive to altered pathophysiological states. In vivo studies in rodents have shown that cardiac glycophagy is activated in response to fasting, over a 24-48 h period 4 . Cardiomyocyte exposure to insulin in vitro increases glycogen content and STBD1 protein expression, with no change in GABARAPL1 (REF. 50 ). This observation suggests that, whereas insulin-stimulated cardiac glucose access might influence the early stages of glycogenrecruitment to autophagosomes, glucose-induced inhibition of lysosomal acid α-glucosidase activity might also occur. In the neonatal heart, elevated acid α-glucosidase activity is observed, and glycogen can be visualized in autophagic vacuoles by electron microscopy, during the postnatal period of nutrient deprivation 51, 52 . More detailed dissection of the cardio myocyte regulatory pathways of insulin signalling, glucose response, and glycophagy induction is required.
In addition to STBD1, glycogen synthase (the ratelimiting enzyme of glycogen synthesis) could serve as an alternative or additional adaptor and method of glycogen recruitment to the autophagosome. Glycogen synthase contains an Atg8-interacting motif and, in nonmammalian species, molecular interaction has been confirmed 53 . In noncardiac tissues, colocalization of Atg8 and glycogen synthase has been reported in response to fasting, indicative of the potential for a nutrient-sensing mechanism for activation of glycophagy 54 . Nutrient regu lation of glycophagy is also apparent at the level of the lysosome, demonstrated by hyperglycaemia-induced inhibition of acid α-glucosidase activity in neonatal rat hepatocytes 55 . The existence of a similar nutrient-sensing glycophagy trafficking pathway involving glycogen synthase remains to be established in the heart. This route of glycogen shunting could be an important component of energy homeostasis not previously appreciated.
Crosstalk between the signalling pathways that regulate glycogen and autophagy might have an important role in synchronizing synthesis and breakdown of glycogen. Although the literature relating to cardiac findings is limited, some insights have been gained from studies in noncardiac tissues. In neurons, knockdown of glycogen branching enzyme (also known as 1,4-α-glucanbranching enzyme) inhibits autophagy and, conversely, activation of autophagy by treatment with rapamycin inhibits glycogen synthase activity 56 . In a mouse model of Lafora disease (a genetic neurodegenerative condition characterized by abnormally branched and insoluble intracellular glycogen deposits), the glycogen overload and associated impairment of autophagy was mitigated when glycogen synthase deficiency was induced 57 . These observations prompted speculation that glycogen accumulation might be a cause, rather than a consequence, of impaired autophagy, at least in this genetic context of glycogen storage abnormality 54 .
Taken together, the evidence of functional glycophagy in the heart, and the long-established cardiac pathologies associated with so-called glycogen storage diseases 58 , highlight the importance of understanding the interplay between the mechanisms controlling enzymatic degradation of glycogen in the cytoplasm and autophagosome-sequestered bulk breakdown. The role of glycophagy in acute and chronic cardiac disease is yet to be elucidated. Given the evidence that glycophagy is potentially regulated by nutrient status, research directed towards understanding the glycophagic response in metabolic stress-related cardiac pathology is an important priority. 30, 59 . Autophagy is essential for neonate survival during the period of nutrient depriv ation immediately after birth 3 and, interestingly, timely withdrawal of this initial autophagy burst is also necessary for postnatal cardiac function 60 . Systemic insulin release at the onset of feeding triggers activation of the insulin signalling pathway to suppress cardio myocyte autophagy 61 . In mice with impaired cardiac insulin signalling (cardiomyocyte-specific Irs1 and Irs2 deletion), the postnatal autophagic surge is not attenuated by feeding and results in cell loss, heart failure, and premature death 60 . In the adult heart, a similar restrained autophagic response to energy stress seems to be required. Whereas induction of autophagy is required during fasting for maintenance of heart function 30 , over-activation of autophagy was associated with cardiac atrophy in fasted mice deficient in insulin-like growth factor 1 (REF. 59 ). The insulin signalling pathway involves activation of PI3K, RAC-α serine/threonineprotein kinase (Akt), GTP-binding protein Rheb, and mTOR, resulting in inhibition of autophagic activity (FIG. 3) . In vitro, activation of autophagy via downregulation of the Rheb-mTOR signalling pathway is essential for cardiomyocyte survival, as shown by accelerated cell death with 18 h of glucose deprivation in cardiomyocytes overexpressing Rheb 62 . Similarly, in response to cardiac ischaemia in vivo, Rheb overexpression prevents ischaemia-induced autophagy and increases infarct size 62 . These findings suggest that activation of autophagy elicits a prosurvival response in cardiomyocytes, but in other contexts, cardiomyocyte over-activation of autophagy has been linked to cell death. An improved understanding of the beneficial and harmful actions of cardiomyocyte autophagy is required to define cardioprotective therapies in various contexts.
Signals that regulate autophagy
Modulation of autophagy in response to cardiac energy stress is regulated by a network involving 5ʹ-AMP-activated protein kinase (AMPK) and insulin signalling pathways (FIG. 3) . Crosstalk and feedback mechanisms are apparent in these signalling networks, but the complexities are not well understood.
Nutrient-sensing mTORC1 could have an important role in integrating metabolic signals to induce autophagy, and receives signals from both AMPK and insulin 22 . When activated, mTORC1 inhibits both ULK1 (a key instigator of autophagosome formation 23 ) and TFEB (a transcription factor for lysosomal autophagy genes 24 ). mTORC1 seems to be particularly sensitive to changes in amino acid availability to regulate macrophagic protein breakdown 22 . Feedback regulation of autophagy via lysosomal breakdown products (including amino acids, glucose, lipids, and DNA) might provide important regu latory input to upstream autophagic signalling pathways. Further understanding of these mechanisms and their role in cardiac metabolic stress settings is required.
Research suggests that Beclin 1 is an important regulator of autophagy in the heart 11 . Bcl-2 or Bcl-2-like protein 1 (Bcl-X L ) proteins bind to Beclin 1 and negatively regulate autophagy; evidence exists that phosphorylation regulates this interaction. Phosphorylation of Beclin 1 at Thr108 promotes interaction between Bcl-2 and Beclin 1 and inhibits cardiomyocyte autophagy 63 . Conversely, phosphorylation of Beclin 1 at Thr119 promotes dissociation of Bcl-2 and Beclin 1 and subsequent activation of autophagy 64, 65 . However, direct evidence for phosphorylation of Beclin 1 in cardiomyocytes is not yet available. In response to fasting, Bcl-2 is phosphorylated at Thr69, Ser70, and Ser87, which inhibits the interaction between Bcl-2 and Beclin 1 and promotes autophagy 66 . Further investigation of Beclin 1 and Bcl-2 phosphorylation in cardiac disease will be informative.
MicroRNA signalling in autophagy MicroRNAs (miRNAs) are short noncoding RNAs that negatively regulate gene transcription. Emerging evidence suggests that miRNAs have an important role in regulating autophagy in the heart. To date, approximately 20 mi RNAs have been shown to target autophagyrelated genes in the heart. These include miR-30a (which targets Beclin 1) 67 , miR-30e (which targets Atg5) 68 , and miR-212 and miR-132 (both of which target forkhead box protein [FOX] O3, a transcription factor targeting autophagy-related genes) 69 . All these miRNAs decrease autophagy (FIG. 3) . Conversely, miR-99a 70 and miR-153 (REF. 71 ) increase autophagy by targeting mTOR and Mcl-1 (induced myeloid leukaemia cell differenti ation protein, a 'stress sensor' that activates autophagy), respectively. The cardioprotective effects of miR-145, which targets fibroblast growth factor receptor 2, have been shown to be mediated by autophagy upregulation in a rodent model of myocardial infarction 72 . In noncardiac tissues, evidence suggests that miRNAs might regulate pathways of cargo-selective autophagy. For example, miR-181a targets Parkin to reduce mitochondria-selective autophagy 73 , and miR-195 targets GABARAPL1 (REF. 74 ), which has been implicated in glycogen-selective autophagy 49 . The panoply of miRNA autophagy targets suggests a nuanced approach, whether it be tissue-specific, cargo-selective, restricted to specific signalling pathways, or related to different stages of autophagic processing.
miRNAs are a major component of exosomesvesicles secreted by cells -that might be important in stem cell cardiac therapies, where miR-146a-3p has been shown to have a role 75, 76 . In the heart, cardioprotection elicited by remote preconditioning is reported to be mediated through exosomes 77 , although the miRNAs involved have not yet been identified. The identification of further mi RNAs as having regulatory actions on cardiac autophagy is anticipated. miRNAs could provide an effective therapeutic approach for modulating autophagy in cardiac disease. The surge of interest in this field promises an improved understanding of miRNA regulation of cardiac autophagy in the near future.
Mechanisms of cardioprotection
Whether upregulation of autophagy is cardioprotective or damaging to the heart is the subject of considerable debate. As evidence emerges, the detrimental effects of both 'too little' and 'too much' autophagy are becoming apparent. Identifying therapeutic opportunities for modulation of autophagy in cardiac disease relies on the understanding of 'how much is too much?' . In many instances, extrapolation of findings from studies in noncardiac cells is necessary, as large knowledge gaps exist in the field of cardiac autophagy.
Autosis is a type of programmed cell death linked with autophagy. In noncardiac cells, cell death induced by activation of autophagy (via Tat-Beclin 1 peptide) is not abrogated by inhibition of apoptosis or necrosis, demonstrating that an independent cell death pathway exists 78 . In neural cells, autotic death occurs in response to nutrient-deprivation in vitro, and in response to hypoxia-ischaemia in vivo 78 . Autosis is characterized by fragmented endoplasmic reticulum, focal plasma membrane rupture, nuclear membrane convolution, numerous autophagolysosomes, and swollen mito chondria. Cell death by autosis can be prevented by inhibitors of autophagy, but not by inhibitors of apoptosis or necrosis 78 . Interestingly, autosis has a unique dependence on the Na + /K + -ATPase, demonstrated by complete abrogation of cell death induced by Tat-Beclin 1 with cardiac glycosides 78 . In cardiomyocytes, direct evidence that overactivation of autophagy is associated with autotic cell death is not yet available. However, data indicating that 'too little' autophagy is associated with cell death have been reported. Cardiomyocyte death induced by β-adrenergic autoantibodies is linked with decreased autophagy, and cardiac function is preserved by rapamycin-induced activation of autophagy 79 . The attachment of small ubiquitin-like modifier proteins (SUMOylation) onto autophagy proteins has been demonstrated, and is coincident with upregulation of autophagy, improved protein quality control, and decreased morbidity in cardiac proteotoxic disease 80 .
In the setting of acute energy stress, induction of autophagy is undoubtedly beneficial. Numerous studies have demonstrated that inhibition of autophagy during acute fasting, nutrient withdrawal, and cardiac ischaemia leads to deleterious outcomes 62, 65 . Furthermore, activation of autophagy during ischaemia-reperfusion elicits acute cardioprotection 30, 42 . Whether sustained autophagy is adaptive or maladaptive in chronic cardiac diseases (such as cardiomyopathy and heart failure) is not yet clear. The commentary below outlines the evidence that supports or refutes a beneficial role for autophagy in various cardiac pathologies, and highlights opportunities for therapeutic intervention.
Autophagy in cardiac pathology
Evidence is accumulating that disrupted autophagy is involved in a diverse range of cardiopathologies. Disturbance in cardiomyocyte autophagy has been reported in the chronic settings of heart failure 81 , hypertrophic and dilated cardiomyopathies (genetic and nongenetic forms) 82, 83 , cardiac ageing 84, 85 , the cardiac sequelae of diabetes mellitus 86 and obesity 87 ; and in the acute settings of sepsis 88, 89 and ischaemia-reperfusion injury 90, 91 . Cardiomyopathy associated with chemotherapeutic agents, such as doxorubicin, also involves disruption of autophagy with impaired cardiomyocyte autophagosome clearance 92 . Cardiac oxidative stress is closely linked with disturbance of autophagy in many pathophysiological settings, and induction of cardio myocyte autophagy in sepsis has been postulated to limit ROS production, thus suggesting a potential therapeutic target 89 . The focus of the discussion below is on the current evidence supporting the involvement of autophagy in several chronic and highly prevalent cardiac disease states.
Heart failure and hypertrophy. Autophagic vacuoles are abundant in failing human and rodent hearts 93, 94 , but whether autophagy is cardioprotective or contributes to pathology in this setting has not been established. Cardiac hypertrophy as a precursor to heart failure is a hallmark of remodelling in most settings. Angiotensin II is an important mediator of cardiac remodelling associated with the hypertrophic response to pressure load and to acute injury, and is involved in the regulation of cardio myocyte autophagy via reciprocal actions of the angiotensin II type 1 (AT 1 ) and type 2 (AT 2 ) receptors 95, 96 . In rodent models of cardiac hypertrophy induced by transverse aortic constriction surgery or administration of isoprenaline, an initial (1-week) decrease in markers of autophagy is observed, followed by upregulation of autophagy with longer-term (9-week) hypertrophic stimulus 97, 98 . When transverse aortic constriction surgery is performed experimentally using a genetic model in which autophagosome formation is suppressed, cardiac hypertrophy and systolic dysfunction are prevented 26 . These findings are corroborated by a more-targeted approach, in which mice with inhibition of cardiomyocyte-specific autophagy (via α-myosin heavy chain [MHC]-Beclin 1 knockdown) were found to have less severe systolic dysfunction than wild-type mice after thoracic aortic banding, without altered cardiac dimensions 99 . Conversely, activation of cardiomyocytespecific autophagy (via α-MHC-Beclin 1 overexpression) exacerbates hypertrophic remodelling and systolic dysfunction 99 . These findings suggest that low baseline autophagy primes the heart to withstand a hypertrophic insult, and high baseline autophagy increases susceptibility to cardiac remodelling and dysfunction in heart failure induced by pressure overload. However, not all studies support this contention. When cardiomyocytespecific tamoxifen-induced Atg5 deletion was used to inhibit cardiomyocyte autophagy in mice aged 8 weeks, just 2 weeks before hypertrophy induction by transverse aortic constriction surgery, cell death and systolic dysfunction are accelerated, with no change in hypertrophic remodelling 2 . Similarly, inhibition of cardio myocyte autophagy (via α-MHC-Beclin 1 knockdown) promotes heart failure progression in a mouse model of proteotoxicity (desmin-related cardiomyopathy; CryAB R120G mice) 94 . Conversely, in vivo activation of autophagy by administration of rapamycin immediately after aortic banding surgery 100 or thyroid hormone treatment 101 in mice prevents hypertrophic remodelling (functional outcomes were not evaluated). In patients with dilated cardiomyopathy, the presence of autophagic vacuoles in biopsies from the left ventricle predicted better outcomes over a 12-year period of follow-up 82 , suggesting that an autophagic response is beneficial for long-term myocyte integrity in pathological settings.
Age-related cardiac remodelling and dysfunction have been linked to disturbances in autophagy 84, 102 . A role for autophagy in the ageing heart is supported by evidence that activation of autophagy via calorie restriction 103 slows the progression of age-related cardiac pathologies. By contrast, inhibition of autophagy via cardiomyocytespecific deletion of Atg5 (REF. 104) 106 , accelerates age-related cardiac dysfunction and hypertrophy and induces premature death relative to wild-type mice. Loss of ischaemic cardioprotection by isoprenaline-preconditioning with age can be restored by antioxidant-induced upregulation of autophagy 107 . However, inconsistent findings showing increased 103, 108 , decreased 85, 104 , or unchanged 109 expression of cardio myocyte markers of autophagy with age have been reported. The use of lysosomal inhibitors to measure the extent of autophagy throughput in young (aged <6 months) versus older (aged >12 months) mice suggests that impaired autophagosome clearance could have a role in age-related cardiac pathology 84, 107 . Assessment of human right atrial samples from individuals aged 33-87 years has shown that, although basal cardiac autophagic activity is reduced with ageing, the autophagic response to ischaemia seems to be preserved 84 , thus supporting the viability of treatments target ing autophagy in older patients. Hypermethylation of autophagy genes in the white blood cells of aged mice 110 could be indicative of generalized age-related impairment of autophagy; whether a similar epigenetic mechanism has a role in cardiomyocyte autophagy is yet to be investigated.
Ischaemia-reperfusion injury.
Autophagy has an important role during energy stress associated with cardiac ischaemia and subsequent reperfusion -a common consequence of coronary artery disease, and an increasingly recognized consequence of coronary microvascular dysfunction. Ischaemic activation of autophagy promotes cell survival and improves cardiac function 91 , but whether autophagy is also beneficial during the reperfusion period is yet to be established. A complex sequence of shifts in energy intermediates and autophagy signals are enacted during ischaemiareperfusion (FIG. 4) . During cardiac ischaemia, the rapid depletion of ATP leads to AMPK activation and stimulation of autophagy 90 . With reperfusion, ATP levels are at least partially restored, but reoxygenation of the tissue is associ ated with a surge in production of ROS, and AMPK activity can remain elevated 111 . Ischaemia also triggers inactivation of GTP-binding protein Rheb, which in turn leads to mTORC1 inhibition providing a parallel autophagy stimulus. Cardiomyocyte-specific Rheb overexpression promotes mTORC1-induced inhib ition of autophagy during ischaemia, and increases ischaemic injury in mice 62 . Whether the changes in Rheb/mTOR signalling are sustained or reversed during reperfusion is yet to be established. Interventions that further activate AMPK and inhibit mTOR activity to promote autophagy during ischaemia might confer additional cardioprotection 112 . Indeed, activation of autophagy contributes to cardioprotection in established interventions, including preconditioning 113 and postconditioning 114 , in addition to various pharmacological agents 39, 42, 115, 116 . Another important node in the autophagic response to ischaemia-reperfusion is glycogen synthase kinase-3β (GSK-3β), which was originally identified as a regulator of glycogen synthesis. GSK-3β has now emerged as a critical signalling protein involved in the response to ischaemia and hypertrophic remodelling 117 . Ischaemic activation of GSK-3β via Ser9 dephosphorylation promotes autophagy, which is subsequently reversed upon reperfusion via Ser9 phosphorylation. Phasic regulation of GSK-3β during ischaemia-reperfusion is assumed to be adaptive, because interventions that inhibit GSK-3β during ischaemia or activate during reperfusion are both detrimental to the heart 118 . The role of autophagy during reperfusion is not clear, and findings of both increased and decreased autophagosome clearance have been reported [119] [120] [121] . When cardiomyocyte autophagy is inhibited (using cardiomyocyte-specific tamoxifen-induced Atg7 knockout) just before in vivo myocardial infarction in mice, cardiac remodelling and dysfunction are exacerbated after infarction 122 . Cardiac expression of FOXO1, the transcription factor that targets multiple autophagyrelated genes (FIG. 3) , is suppressed after myocardial infarction, with only partial recovery after 7 days 123 . Forced expression of the active form of FOXO1 (constitutively deacetylated) attenuates adverse remodel ling associated with myocardial infarction, which is probably associated with upregulated autophagy (although not measured in this study) 123 . A decrease in lysosome biogenesis could lead to impaired autophagy and accumu lation of autophagosomes during reperfusion, as demonstrated by decreased autophagosome clearance (extent of LC3 increase with chloroquine administration) Transverse view of the heart showing the ischaemic 'at risk' zone (grey) and the postreperfusion necrotic area (black). During ischaemia (blue shaded area), activation of autophagy is linked with ATP depletion, activation of 5ʹ-AMP-activated kinase (AMPK) and glycogen synthase kinase (GSK)-3β, and inhibition of mechanistic target of rapamycin complex 1 (mTORC1). During reperfusion (pink shaded area), a surge in the production of reactive oxygen species (ROS) is associated with inhibited GSK-3β activity and ATP levels are at least partially restored. Question marks highlight areas of uncertainty requiring further investigation. Some data indicate that sustained mTORC1 inhibition and AMPK activation are linked with elevated autophagy during reperfusion. and a eduction in lysosome-associated membrane glyco protein (LAMP) 2, a protein implicated in maintaining lysosomal membrane integrity, lysosomeautophagosome fusion, and lysosome motility 121 . During reperfusion, increased cardiac expression of the protein Beclin 1 is evident, an effect that has been demonstrated to be mediated by ROS 124 . Paradoxically, increased Beclin 1 expression during reperfusion has been implicated in the down regulation of lysosomal gene transcription (via inhibition of TFEB) 124 ; therefore, suprabasal Beclin 1 levels might suppress autophagosome clearance. Suppression of Beclin 1 by short hairpin RNA rescues ROS-induced cell death in cultured neonatal cardiomyocytes via TFEB, and upregulation of Beclin 1 (via adenoviral Beclin 1) suppresses lysosome biogenesis 121, 124 . The complexities of feedback loops involved in the regulation of autophagosome and lysosome biogenesis are only just beginning to be understood. Other autophagy-related proteins are also likely to have dual roles in activating and suppressing autophagic activity, depending on expression thresholds.
Diabetic cardiomyopathy. The earliest reports identifying disturbance of cardiomyocyte autophagy in experimental models of diabetes mellitus revealed discordant findings. First, upregulation of autophagy in rodents with type 2 diabetes (fructose diet model) was described 125 and, almost simultaneously, downregulation of autophagy was reported in a mouse model of type 1 diabetes (streptozotocin-induced pancreatic β-cell ablation) 126 . Despite the rapid expansion of the experimental literature on this subject, which also includes some evaluation of clinical samples, a consensus in the field regarding a protective or detrimental role of autophagy in diabetic cardiomyopathy has not yet been achieved. From detailed examination of all the available studies, a conclusion on the direction of cardiomyocyte autophagy modulation in response to diabetes cannot be reached. Furthermore, differences in the reported findings cannot be easily attributed to species, the type or model of diabetes, or disease duration (TABLE 1) .
A comparison of findings from studies measuring 'snapshot' autophagy markers under basal conditions reveals that approximately equal numbers of studies report an increase or a decrease in the expression of markers in diabetes compared with nondiabetic controls. Reports from a few studies indicate no change in levels of autophagy marker (or ambiguous findings) in the presence of diabetes. Measurements of autophago some clearance have been reported in several experimental models of diabetes, determined by the extent of autophagy marker accumulation observed with acute lysosomal block via bafilomycin or chloroquine. These studies show an increase 127 or decrease [128] [129] [130] [131] [132] [133] in the rate of autophagosome clearance in the hearts of animals with diabetes relative to controls. In humans with type 2 diabetes and ischaemic heart disease, tissue expression of lipidated LC3 and Beclin 1 in the right atrial appendage is increased, expression of p62 is decreased, and immunovisualization of cardio myocyte LC3 and Beclin 1 is augmented with accumulation of autophagosomes 127 . By contrast, a decrease in cardiac Atg5 expression, and no change in LC3, was reported in another group of patients with type 2 diabetes 134 . The autophagic response to metabolic stress induced by fasting or ischaemia is blunted in mice with obesity and insulin resistance 62, 131 , a finding that might underlie exacerbated ischaemic injury in the presence of diabetes. Glycophagy could also have an important role in the cardiomyocytes of individuals with diabetes, coincident with disturbances in glycogen metabolism 50 . Understanding the progression and nuances of autophagy in diabetic cardiomyopathy is an important priority, and investigating cargo-selective pathways of autophagy could provide crucial revelations in this field. A systematic understanding of the discrepant findings that could be ascribed to differential signalling in type 1 and type 2 diabetes is required 86 .
Interventions to manipulate cardiomyocyte autophagy in the context of diabetes have been informative. However, inconsistent findings again prevent firm conclusions from being made as to whether autophagy is adaptive or maladaptive in this setting. In support of the contention that autophagy has a beneficial role in the heart of individuals with diabetes, studies have shown that activation of autophagy via fenofibrate 135 , metformin 126, 136 , ghrelin 137 , or resveratrol 138 remediates diabetes-induced cardiac dysfunction, and inhibition of autophagy via chloroquine exacerbates diabetes-induced diastolic dysfunction 138 . By contrast, other studies have shown that autophagy could have a detrimental role in diabetic cardiomyopathy. Inhibition of autophagy via epigallocatechin-3-gallate 139 , chloroquine 140 , global Becn1 (Beclin 1) haploinsufficiency 130 or global Atg16l1 (Atg16L1) deficiency 130 rescues diabetes-induced cardiac pathology. Given that these studies employed either systemic delivery of autophagy-related pharmacological agents (intraperitoneal injection or oral gavage) or whole-body genetic manipulation, the systemic or noncardiac tissue changes are likely to have influenced cardiac outcomes. In only one report published to date has an intervention targeted towards cardiomyocytespecific autophagy been investigated directly in hearts affected by diabetes. In mice with streptozotocininduced type 1 diabetes, activation of cardiomyocyte autophagy via α-MHC-Beclin 1 overexpression exacerbated diabetes-induced cardiac pathology 130 . The hearts of these mice seemed to show enhanced autophagosome clearance (determined by bafilomycin-induced LC3-II accumulation) 130 . Therefore, the previously reported inhibitory actions of Beclin 1 on lysosomal bio genesis 124 were unlikely to be involved in this instance. These findings suggest that autophagy has a detrimental role in diabetic cardiomyopathy, and direct activation of cardiomyocyte autophagy might not be a viable therapeutic option in this setting.
Potential therapies
Clinical evaluation of autophagy as a therapeutic target has, to date, primarily been focused on applications for cancer, involving rapamycin (or so-called rapalogue agents) or utilizing hydroxychloroquine (usually as an adjuvant therapy) 141 . In relation to cardiopathology, autophagy is a potentially attractive therapeutic target, particu larly in the contexts of ischaemic preconditioning 113 and proteostasis 142 . In the experimental setting, numerous agents that promote cardiomyocyte autophagy have been identified, including rapamycin [143] [144] [145] , activators of NAD-dependent protein deacetylase sirtuin 1 (such as NAD + (REF. 146)), hydrogen sulfide 147 , various cardio protective agents (for example, diazoxide, ranolazine, and uridine-5ʹ-triphosphate) 113 , and common clin ical therapies such as statins 42 and metformin
126
. Cell-permeable Tat-Beclin 1 has also been shown to promote cardio myocyte autophagy in vivo 81 . Histone deacetylase inhibitors have been demonstrated to reduce infarct size in association with stimulation of autophagic flux 148 , as well as exerting antihypertrophic effects in experi mental models of hypertrophy 27 . Both effects are likely to be mediated in part through mTOR inhibition 149 . Inhibition of autophagy might be beneficial in a number of settings including diabetic cardiomyopathy 61, 130 and some hypertrophic states 150 . However, more work is required to elucidate appropriate targets, timing and dosage, and cardiac delivery methods. Few inhibitors of autophagy have been identified; these include 3-methyl adenine and wortmannin, which target PI3K, and chloroquine and bafilomycin, which target autophagosome-lysosome fusion. However, offtarget effects could influence outcomes, because PI3K is involved in various signalling pathways in addition to regulation of autophagy, and anti-inflammatory actions of chloroquine have been demonstrated 151 . Inhibition of AMPK with compound C (dorsomorphin) is an indirect method of preventing autophagy, but the efficacy of this potential therapeutic approach in a range of cardiopathologies involving autophagy upregulation remains to be demonstrated 147 . As autophagy is essential for cardiac homeostasis, long-term inhibition is likely to be deleterious 104 . Indeed suppressed cardiomyocyte autophagy results in an increased susceptibility to cardiac damage induced by acute energy stress in situations such as fasting or ischaemia 152 . Positive and negative regulation of Beclin 1, via phosphorylation induced by Mst1 (also known as serine/ threonine-protein kinase 4) and Rho-associated protein kinase 1, respectively, might provide a novel tool for manipulation of autophagy 63, 65 , and an improved understanding of these kinases in the heart will be informative. As discussed above, interest is increasing in the potential use of mi RNAs as cardiac therapeutic targets. Through an miRNA library screen, miR-22 was identified as being upregulated in the ageing heart and is associated with diminished autophagy 153 . Inhibition of miR-22 is associ ated with upregulated autophagy, mitiga tion of remodel ling after infarction, and improved cardiac function 153 . Of note, these effects seem to be agedependent, as inhib ition of miR-22 was less effective in younger animals than in older animals 153 .
Although clinical studies designed to assess cardiac end points relating to treatment targeting autophagy have yet to be undertaken, various agents already in clinical use (such as verapamil 154 , metformin 126 , and rapamycin 145, 155 ) have been identified to elicit effects on cardiomyocyte autophagy. The nonselective β-adrenergic receptor agonists isoprenaline and noradrenaline, and the selective β 2 -adrenergic receptor agonist salbutamol, were reported to increase autophagic flux in rat cardiac fibroblasts, which was blocked by propranolol 156 . Confusingly, propranolol has also been reported to stimulate autophagy 157 . Statins stimulate autophagy and mitophagy 42 , but whether the cardioprotective benefit of statins is dependent on autophagy is unknown. Early results from the Statin for Acute Myocardial Infarction Trial (SAMIT) 158 show improved left ventricular ejection fraction at 6 months after infarction in patients who were assigned to receive atorvastatin commencing at the time of hospital admission (10 mg per day for 30 days), followed by percutaneous coronary intervention for the affected vessel, suggesting a cardioprotective effect of statins. However, in another trial, patients who received a higher dose of atorvastatin maintained for a shorter period of time (80 mg per day for 7 days) than in SAMIT, did not show a functional cardiac benefit on imaging at 3 months 159 . The histone deacetylase inhibitor suberoylanilide hydroxamic acid (vorinostat), which is FDA-approved therapy for cancer, has been reported to attenuate myocardial reperfusion injury by inducing cardiomyocyte autophagy in rabbits 148 . A major limitation in translating experimental interventions that target autophagy into treatments for human cardiac pathologies is the difficulty in measuring autophagy in heart tissue in the clinical setting. Noninvasive imaging tools for direct monitoring of autophagy are not yet available, although a promising advance in rodent in vivo imaging of rapamycin modulated lysosomal activity (with a cathepsin-activatable fluorochrome) has been reported 143 . Current autophagy 'snapshot' analyses require cardiac tissue sampling. Measuring autophagosome clearance clinically would require tissue biopsy before and after administration of a lysosomal inhibitor -a challenging prospect. Development of a noninvasive imaging modality for autophagy will be a major advance, allowing assessment of efficacy of potential therapeutic interventions.
Conclusions
Disturbances in cardiomyocyte autophagy have now been identified in a plethora of cardiac pathologies, of either genetic or nongenetic aetiology. Whether autophagy is beneficial or detrimental in each setting has been difficult to establish, and seems dependent on context. Indeed, a differential role for autophagy in acute versus chronic disease is evident. Short-term activation of autophagy might confer cardiac benefit, whereas the sustained effects of elevated autophagy could have detrimental consequences. Much of the variability reported in altered autophagic activity in cardiac disease is likely to reflect diversity in type, severity and longevity of disease. Careful longitudinal experiments are required to map altered autophagic activity through the progression of acute and chronic disease states to establish the adaptive or nonadaptive value of autophagic activity. With this information, the identification of optimal intervention time points will be feasible, and it will be possible to determine whether suppression or augmentation of autophagy is beneficial. Research is required to discern how interventions should be designed to titrate autophagic activity for optimal cardioprotection, and consistent implementation of assays to evaluate autophagy throughput in various circumstances is also needed. Understanding how disrupted autophagy progresses to cardiomyocyte death by autosis is also an important research priority.
With the identification of cargo-selective autophagy subtypes (macrophagy, mitophagy, glycophagy, and others), and with expanding knowledge of complex autophagy regulatory and signalling networks, development of targeted interventions (including small molecules) could provide useful therapeutic avenues. Given the discovery that subpopulations of autophagosomes are often (but not exclusively) cargo-selective, subpopulations of lysosomal structures with matched enzyme complement could be anticipated to exist. Such lysosomal structures could be unique sites for therapeutic targeting. A largely neglected area of autophagy research is the investigation of the routes of autophagolysosome efflux of degraded autophagy substrates. This end point of the cell recycling machinery could be an important locus of therapeutic intervention. The challenges of intervening in any cellular process of fundamental homeostatic importance, and avoiding damaging off-target effects, are considerable. Harnessing knowledge of autophagic mechanisms for interventional potential is an ambitious undertaking; but if lessons learned from apoptosisdirected cancer therapeutics are taken as a guide 160 , the coming decade will be a time of major translational cardiomyocyte autophagy advance.
